AEAleksei I. Ermakov

Aleksei I. Ermakov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aleksei I. Ermakov has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • HIV-1 drug resistance profile in patients with inefficient antiretroviral therapy containing elsulfavirine

    by A. A. Kirichenko, D. E. Kireev, A. V. Kravchenko, I. A. Lapovok, N. V. Sizova, N. E. Monakhov, A. I. Ermakov, M. V. Pitersky, A. V. Semenov, M. R. Bobkova, et al.

    The aim . To determine the HIV-1 drug resistance profile in patients with virological failure to elsulfavirine-containing antiretroviral therapy in a real-world clinical setting. Materials and methods . The study group consisted of HIV-1 nucleotide sequences ( pol gene fragments encoding protease and part of reverse transcriptase) from 179 HIV-infected patients with virological failure of elsulfavirine-containing antiretroviral therapy and who had not previously received other non-nucleoside reverse transcriptase inhibitors. Resistance mutations were identified and HIV-1 drug resistance was determined using the HIVdb database (v. 9.8). Results and discussion . HIV-1 mutations associated with viral resistance to non-nucleoside reverse transcriptase inhibitors were detected in 88.3% of patients with virological failure of elsulfavirine-containing antiretroviral therapy. Previously described HIV-1 resistance profiles to elsulfavirine were detected in only 5.1% of the studied patients. A total of 29 mutations were detected, the most common being V106I (46.9%), E138K (38.5%), H221Y (34.6%), E138Q (20.7%), F227C (12.3%), Y181C (11.7%), K101E (11.2%), and E138A (10.6%). A total of 87 different HIV-1 mutation patterns were detected, with combinations of two or more mutations predominating (70.9%). The main patterns detected included combinations of mutations V106I/M, E138K/Q/G, and H221Y±K101E, F227C, G190S, and M230L. High levels of HIV-1 resistance in the studied patients were most frequently detected to rilpivirine (60.9%), which limits its successful use in patients taking elsulfavirine, and least frequently to doravirine (22.9%) and etravirine (9.5%), which allows them to be considered as options for switching. Conclusion . This study identified the main mutations associated with elsulfavirine-containing therapy failure, potential pathways for the development of HIV-1 resistance to the drug, and HIV-1 cross-drug resistance to other drugs in class. However, most of the patterns identified in this study have not been previously described, indicating the need to update data on the HIV1 resistance profile to elsulfavirine.

  • Open Access

    Characteristics of glucose metabolism and endothelial status in young patients with perinatal HIV infection

    by A. V. Samarina, E. J. Sereda, V. V. Rassokhin, A. I. Ermakov, O. V. Teslya

    The aim of the study: to assess the vascular endothelial status (based on brachial artery ultrasound data and the Celermajer test) and glucose metabolism markers (insulin, glucose levels, HOMA-IR index) in young patients with perinatal HIV infection.Materials and methods. The study included 83 young HIV-infected patients aged 18 years or older registered at the St. Petersburg AIDS Center. The main group (n=57) consisted of patients with perinatal HIV infection (PHIV), while the control group (n=26) included individuals infected via sexual transmission.Results and discussion. In the main group, 46 patients (80.7%) had normal blood glucose levels (3.3–5.5 mmol/L), compared to 11.6% in the control group. Normal insulin levels were observed in 84.2% of the main group and 77% of the control group. A pathological HOMA-IR index was significantly more frequent in the main group (p0.05). Both groups exhibited early signs of endothelial impairment at ages 20–25, with intima-media thickness (IMT) within normal ranges. However, males with PHIV showed significantly more frequent deviations toward increased IMT (p=0.049).Conclusion. Markers of glucose metabolism disorders, insulin resistance, and vascular endothelial dysfunction were identified in young patients with perinatal and sexually acquired HIV. However, PHIV patients demonstrated earlier and more pronounced changes.

  • Open Access

    Molecular genetic monitoring of HIV-1 variants circulating in St. Petersburg

    by N. E. Monakhov, A. I. Ermakov, E. S. Obizhaeva, T. N. Vinogradova, D. A. Lioznov

    The aim of the study: to assess the genetic diversity of HIV-1 variants circulating in St. Petersburg.Materials and methods. The study included 289 patients with virological ART failure in 2022 in the St. Petersburg AIDS Center. Fragments of the pol gene encoding integrase, reverse transcriptase and protease were analyzed by polymerase chain reaction and Sanger sequencing. Phylogenetic tree created by the Neighbor-joining method with 1000 repeats of nucleotide sequences, bootstrap values >70. To assess the circulation of HIV genovariants in dynamics in St. Petersburg, sequences and clinical and laboratory parameters obtained from 544 patients since 2018. The total sample included 833 samples (289 were collected in 2022), compared with the results of a study from 1104 HIV-infected patients in 2006–2011.Results and discussion. Monovariants of HIV dominated in the examined patients (95.1%, 275 people), subtype A6 — 88.2% (255 people); subtype B — 5.9% (17 people); C — 0.3% (1 person); G — 0.7% (2 people), the proportion of recombinant forms — 4.9% (14 people). In the sample collection, the proportion of new HIV cases of non-A subtype was 13.3% in 2006–2011, and 11.1% in 2018–2022. A significant increase in the incidence of recombinant forms of HIV-1 was revealed from 1.6% to 3.5% (c2=6.111; p=0.014). In the group (2018–2022), the recombinant form of CRF63_02A6 was more common (15/29 people).Conclusion. Phylogenetic analyses makes it possible to determine HIV subtypes, but also to establish the potential geographical origin of the virus, to identify transmission clusters taking into account the socio-demographic indicators of HIV-infected patients. Molecular epidemiological monitoring can be used to develop and implement programs to counter the spread of HIV among the population. The dominant genetic variant of HIV circulating in St. Petersburg is sub-subtype A6, as it was 10 years ago. The proportion of new cases of infection with non-A subtype of HIV remains stable, with a downward trend. The increase in the frequency of detection of recombinant forms of HIV-1 is probably related to the migration processes of the population.


  • The study of platelet microparticles and P-selectin expression in patients with the peripheral arterial diseases

    by Aleksei I. Ermakov, Larisa B. Gaikovaya, Olga V. Sirotkina, Tatiana V. Vavilova

    BACKGROUND: High platelet reactivity leads to the progression of atherosclerosis and its complications. Activated platelets adhere to the site of endothelium damage on the vessel wall and initiate the formation of an arterial thrombus, followed by acute ischemia of the organ. Biochemical and cellular marker such as platelet microvesicles and P-selectin can be analyzed using flow cytometry, which is based on a specific antigen-antibody interaction. Patients with peripheral arterial disease are at significantly greater risk of cardiovascular and cerebrovascular complications than individuals of the same age and sex. The use of antiplatelet agents is an important part of pathogenetic therapy and prevention of cardiovascular diseases and their complications. AIM: This study was to evaluate the level of platelet microparticles and P-selectin expression in patients with peripheral arterial disease receiving antiplatelet therapy. MATERIALS AND METHODS: The study included 49 people, which included three study groups: patients with obliterating disease of the arteries of the lower extremities (n = 14) on the background of long-term use (more than 14 days) of double (75 mg clopidogrel and 100 mg Acetylsalicylic acid) antiplatelet therapy, patients with COVID-19 (n = 15), who made up the positive control group in the determination of microparticles of platelet origin, and healthy volunteers (n = 20) without signs of acute respiratory disease, without a history of cardiovascular and thromboembolic episodes, not taking antiplatelet drugs. The functional activity of platelets was assessed by two methods: using light aggregometry and analysis of P-selectin expression on platelet surface by flow cytometry. The number of platelets microparticles in blood plasma was also determined using flow cytometry. RESULTS: A significant decrease in platelet aggregation was found in patients with peripheral arterial disease taking antiplatelet agents, compared with controls by used light aggregometry. Similar changes were obtained when analyzing the expression of P-selectin on platelets. A higher percentage of platelets microparticles with the CD9+CD41+ phenotype was found in patients with severe inflammation compared with peripheral arterial disease patients treated with antiplatelet agents and compared with the healthy controls. CONCLUSIONS: Thus, our study reflects the consistency of the results of three different laboratory tests in assessing the platelets reactivity in patients with the peripheral arterial diseases taking antiplatelet drugs.


  • Open Access

    Evaluation of the functional state of mitochondria isolated from mononuclear leukocytes by flow cytometry in patients with chronic heart failure receiving ubidecarenone

    by O. A. Lobanova, L. B. Gaikovaya, V. A. Dadali, A. I. Ermakov, G. A. Kukharchik

    Aim. To evaluate the functional state of mitochondria isolated from peripheral blood mononuclear leukocytes using flow cytometry in patients with chronic heart failure receiving ubidecarenone (coenzyme Q).Materials and methods. The study included 53 patients with chronic heart failure who had experienced myocardial infarction. The patients were divided into two groups: group 1 received optimally chosen standard therapy, while group 2 received optimally chosen standard therapy and ubidecarenone (“Kudevite”). The mitochondrial membrane potential was evaluated by flow cytometry using propidium iodide and 3,3′-dihexyloxacarbocyanine iodide (DiOC6(3)). The levels of coenzyme Q were determined using high-performance liquid chromatography with ultraviolet (UV) detection.Results. A direct correlation was established between the coenzyme Q levels in the blood plasma and the percentage of DiOC6(3)-positive cells (R = 0.39; р < 0.05) in the patients with chronic heart failure. In group 1, no significant differences in the coenzyme Q levels and the percentage of DiOC6(3)-positive and DiOC6(3)-negative cells before and after the therapy were observed. In group 2, a significant increase in the proportion of DiOC6(3)-positive cells and a significant decrease in the percentage of DiOC6(3)-negative cells were revealed.Conclusion. The increase in the functional activity of mitochondria in the patients with chronic heart failure receiving ubidecarenone was identified. Flow cytometry can be used to evaluate the functional state of mitochondria and observe the efficiency of the selected therapy.


  • Open Access

    Monocytic and lymphocytic inflammatory reaction during myocardial infarction complicated with acute heart failure in patients with type 2 diabetes mellitus

    by O. K. Lebedeva, Alexey I. Ermakov, Larisa Gaikovaya, Galina A. Kukharchik, Л. Б. Гайковая

    Background. The processes of inflammation and repair in the area of myocardial infarction (MI) are carried out and regulated by various populations of immune cells, including monocytes, lymphocytes, and NK-cells. The success of myocardial recovery after infarction and the risk of developing acute heart failure (AHF) depend on their adequate interaction. The presence of type 2 diabetes mellitus (T2DM), in which chronic low-gradient inflammation occurs, can affect the monocytic and lymphocytic response in MI, which may contribute to the development of AHF.Objective. to assess the features of monocytic and lymphocytic responses in patients with MI T2DM complicated by the development of AHF.Design and methods. The study included 121 patients with MI T2DM (38 of them with AHF). The control group included 59 patients without diabetes mellitus (including 13 patients with AHF). For all patients within 1 day, on days 3, 5 and 12 of MI, the total number of monocytes and lymphocytes, the monocytes-to-lymphocytes ratio (MLR), subpopulations of monocytes and T-lymphocytes with NK cells (T&NK-cells) were determined by flow cytometry.Results. In patients with T2DM, the number of monocytes of different subpopulations did not differ depending on the development of AHF. In patients without T2DM with MI, complicated by AHF, compared with patients without AHF, on day 3, the number of CD14(+)CD16(-)monocytes was higher: 1018 (824; 1144) vs 593 (557; 677) cells/μL, p Conclusion. In patients with T2DM, the development of AHF is associated with a low number of lymphocytes in the absence of a pronounced monocytic response. In non-diabetic patients, the development of AHF is associated with an increase in CD16(-)monocytes and a lower number of CD16 (+) T&NК-cells.


  • Open Access

    Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management

    by Igor G. Bakulin, Maria I. Skalinskaya, Igor V. Maev, Ekaterina V. Skazyvaeva, Mariia S. Zhuravleva, Larisa B. Gaikovaya, Natalia V. Bakulina, Aleksei I. Ermakov, Ekaterina S. Alekseenko, Kristina N. Ivanova, et al.

    Treatment of inflammatory bowel diseases IBD (Crohns disease, ulcerative colitis) is aimed at achieving clinical, endoscopic and histological remission, minimizing surgical complications, and ensuring a normal quality of life. However, the use of medical treatment is potentially associated with various adverse events, among which infectious complications, malignant neoplasms, as well as myelotoxicity, hepatotoxicity, skin lesions and others. The risk of side effects depends on the type of drug therapy (5-aminosalicylates, thiopurines, biologicals, etc.), the duration of treatment, the presence of extra-intestinal manifestations, etc. The article provides an overview of data on both the effectiveness and frequency of various side effects of the main classes of drugs in IBD, presents methods of investigation which can predict the effectiveness and development of side effects, the implementation of which can be considered as a variant of personalized therapy in IBD.


  • DYNAMICS OF MICROVESICLE FORMATION IN BLOOD IN PATIENTS WITH COVID-19 AT DIFFERENT STAGES OF THE DISEASE

    by O.V. Sirotkina, A.I. Ermakov, Yu.I. Zhilenkova, E.A. Zolotova, D.A. Kudlay, T.V. Vavilova, L.B. Gaykovaya

    Введение. SARS-CoV-2, являясь причиной COVID-19, вызывает развитие пневмонии и острого респираторного дистресс синдрома, а также приводит к развитию сердечно-сосудистых, гематологических и тромбоэмболических осложнений. Механизм развития ковид-ассоциированной коагулопатии в настоящее время до конца не определен, но полагают, что он включает активацию лейкоцитов, эндотелиоцитов и тромбоцитов в результате цитокинового шторма. Активация клеток сопровождается образованием и выбросом в кровоток внеклеточных микровезикул и экзосом.Целью работы явился анализ внеклеточных микровезикул/экзосом клеток крови у больных COVID-19 на разных стадиях заболевания.Материалы и методы. В исследование вошли 18 пациентов с COVID-19, обследованных при поступлении в стационар, и 29 пациентов, выздоровевших от COVID-19 и обследованных при выписке из стационара. Группы сравнения включали 14 человек без признаков ОРВИ, без сердечно-сосудистых и тромбоэмболических эпизодов в анамнезе, и 11 пациентов с эпизодом венозного тромбоэмболизма (ВТЭ) не ранее 3 месяцев до включения в исследование, принимающие в качестве антикоагулянтной терапии варфарин. Всем обследованным был выполнен клинический анализ крови, определен уровень D-димера, С-реактивного белка и сывороточного ферритина, а также измерено количество внеклеточных микровезикул на проточном цитометре с помощью набора реагентов Exo-FACS и флуоресцентно меченых антител к поверхностным маркерам клеток крови.Результаты. Количество микровезикул выше у пациентов с COVID-19 в момент госпитализации по сравнению с контрольной группы и сопоставимо с таковым у больных с ВТЭ. У больных COVID-19 вклад в формирование пула внеклеточных везикул вносят не только тромбоциты, как у больных с ВТЭ, но и лейкоциты. Уровень CD45+ микровезикулу пациентов с COVID-19 при госпитализации в 10 раз превышает таковой у контроля и в 30 раз - у пациентов с ВТЭ и коррелирует с числом лимфоцитов. К моменту выписки у пациентов с COVID-19 уровень внеклеточных микровезикул достоверно снижается и практически не отличается от контрольной группы здоровых лиц.Заключение. Микровезикулы можно рассматривать в качестве потенциальных маркеров активации системы гемостаза и риска развития тромбоэмболических осложнений при COVID-19, коррелирующих с воспалительным ответом и выявляющих отклонения на доклиническом...


  • Molecular mechanisms of hemostasis activation in COVID-19 at the hospital stage

    by T.V. Vavilova, O.V. Sirotkina, A.I. Ermakov, Yu.I. Zhilenkova, L.B. Gaikovaya

    Одним из молекулярных механизмов активации свертывания при COVID-19 являются процессы микровезикуляции клеток. Выраженность этих процессов в зависимости от степени тяжести течения заболевания и связь с клиническими проявлениями тромбозов остается недостаточно понятной. ЦЕЛЬ ИССЛЕДОВАНИЯ Определение характера и количества микровезикул клеток крови и эндотелия у больных с COVID-19 среднетяжелого течения, госпитализированных в стационар. МАТЕРИАЛ И МЕТОДЫ В исследование были включены 43 пациента, госпитализированных в связи со среднетяжелым течением COVID-19 и поражением легких 2-й степени, и 14 лиц контрольной группы без признаков острой респираторной инфекции и факторов риска тромбозов. РЕЗУЛЬТАТЫ Выявлено увеличение количества микровезикул тромбоцитарного, лейкоцитарного и эритроцитарного происхождения (кроме эндотелиальных, которые продемонстрировали снижение по сравнению с контролем) в отсутствие у большинства пациентов повышения уровня D-димера. Отмечена положительная динамика за период госпитализации на фоне этиопатогенетической терапии без нормализации количества тромбоцитарных микровезикул. ВЫВОДЫ Высокая активность формирования клеточных микровезикул у пациентов со среднетяжелым течением COVID-19 отражает потенциальный риск тромбоэмболических осложнений даже в условиях отсутствия повышения уровня D-димера. Процесс микровезикуляции коррелирует со степенью тяжести воспалительной реакции. Этиопатогенетическое лечение с включением в протокол антикоагулянтной терапии позволяет снизить продукцию микровезикул, но не нормализует процесс полностью.


  • HEMATOLOGICAL MARKERS FOR PROGNOSIS OF SURGICAL SITE INFECTIONIN HIP ARTHROPLASTY

    by L.B. Gaikovaya, N.L. Afanasieva, A.N. Tkachenko, A.I. Ermakov, A.A. Vorokov, B.G. Aliev

    Возникновение инфекционных осложнений в области хирургического вмешательства при эндопротезировании ставит перед собой задачу разработки простых доступных лабораторных тестов для прогноза ранних послеоперационных осложнений.Материалы и методы. В исследование было включено 42 пациента, поступивших в клинику травматологии и ортопедии Северо-западного государственного медицинского университета им. И.И. Мечникова для проведения плановой операции по эндопротезированию тазобедренных суставов и 28 доноров, которым проводились исследования крови на автоматическом гематологическом анализаторе DxH800 (BeckmanCoulter, США) и проточном цитометре FC-500 (Beckman Coulter, США) с использованием реактива CytoDiff (Beckman Coulter, США).Результаты и их обсуждение. У пациентов исследования проводились до операции. Ретроспективно пациенты были разделены на 2 группы: 1-я группа без инфекционных осложнений в области хирургической раны (31 человек) и 2-я группа - с инфекционными осложнениями (11 человек). Перед операцией пациенты не имели изменений в гематологических показателях по сравнению с донорами и референтными значениями. У пациентов с инфекционными осложнениями установлено исходное снижение В-лимфоцитов по сравнению с пациентами без инфекционных осложнений. При изучении взаимосвязи В-лимфоцитов с гематологическими расчетными показателями крови установлена взаимосвязь с показателем распределения моноцитов по объему (SD-MO).Заключение. Таким образом, рекомендуется включить оценку содержания В-лимфоцитов в крови в структуру весовых прогностических коэффициентов при расчете индексов развития инфекционного осложнения травматологическим пациентам. А также для прогноза рисков возникновения осложнений использовать показатель, получаемый с гематологического анализатора - ширина распределения моноцитов по...